Neuralink Founder Elon Musk: Visual Implants Within Six Months to a Year
Elon Musk stated that the first visual implants will occur within the next 6 to 12 months; even those who are completely blind from birth can have signals directly written into the visual cortex to produce vision. The long-term goal is ultra-high resolution, with the ability to see infrared, ultraviolet, and even radar, described as superhero-like capabilities.
The product line is called Blindsight, following the cortical visual prosthesis path: an external camera captures scenes, and the implant stimulates the intact visual cortex, bypassing the eyeball and optic nerve. The premise is that the cortex itself can still be driven. Musk mentioned that a monkey's visual implant has been functioning for about three years; in September 2024, the FDA granted breakthrough device designation, which accelerates review but does not equate to market approval.
He has repeatedly compared the first-generation visuals to early gaming consoles or Atari-level low resolution, with high resolution and multispectral capabilities being the path of subsequent electrode density and stimulation algorithms, rather than the immediate experience of the first test subjects. In January 2026, the company announced during the two-year update of Telepathy that it is ready for the first human Blindsight implant, awaiting final regulatory approval; the Austin factory plans to increase N1 production and advance automated surgeries.
Similar cortical solutions include Cortigent's Orion, which are still in the experimental stage, with no large-scale randomized controlled public data available. For those who are blind from birth, the results are more uncertain due to potential cortical reorganization compared to patients who became blind later but still retain a visual map.
Mechanically, the buyers are blind individuals whose optic nerves or eyeballs are destroyed but whose cortex remains intact, along with the trial centers, while the sellers are Neuralink, which possesses robotic implantation and electrode bundle technology. The event is driven by the founder's timeline, with funding coming from medical device financing and subsequent surgical capacity; beneficiaries are the centers entering the first trial cohort, while those under pressure are the regulators and clinical sides still waiting for approval, unable to treat the breakthrough designation as proof of efficacy.
Public information has not disclosed the number of initial human subjects, the final list of trial locations, nor provided human data for infrared, ultraviolet, and radar channels.
Source: Public Information
ABAB AI Insight
Musk directly translates the movement decoding experience from Telepathy to visual writing: the former reads cortical intentions to control a cursor, while the latter writes light points back to the visual cortex. In June 2025, he provided a 6 to 12-month window at a startup event, and in January 2026, he changed his statement to "ready, waiting for approval," indicating that the timeline has already shifted once. The breakthrough designation accelerates dialogue but does not speed up neurons learning to interpret electrical pulses as objects.
The capital path is to first prove that wireless implants can be long-term in paralyzed patients, then sell the same robotic surgical platform for visual indications to open a larger patient base. The motivation is to expand BCI from "replacing hands" to "replacing eyes" and to market the medical device as an enhancement platform through multispectral narratives. Resource mobilization relies on Austin manufacturing and the R1 surgical robot, rather than first publishing large-sample papers on cortical maps.
Comparable entities include Second Sight/Orion's cortical electrodes and retinal chip PRIMA, as well as Musk's repeated advancement of the Starship reuse timeline using the same communication techniques. In terms of industry positioning, BCI has moved beyond pure animal demonstrations and into symptom expansion: movement decoding has human cases, while visual writing remains at the approval doorstep.
Structural judgment pertains to technological substitution: pricing power shifts from the eyeball and optic nerve to "who can stably stimulate the visual cortex." The mechanism is that as long as the cortex can be written to, the eye and optic nerve are no longer the only entry points for vision; however, resolution is limited by electrode density, thermal damage, and plasticity, with the radar vision in the slogan and the first-generation pixel points separated by regulatory batches and years of adaptation training.
ABAB News · Cognitive Laws
Being able to write to the cortex does not equate to having restored vision.
Breakthrough designation accelerates review, not resolution.
The story of super senses usually sells the next generation of electrode density.